Draft genomes of two cystic fibrosis isolates of Stenotrophomonas maltophilia, AU30115 and AU32848

Stenotrophomonas maltophilia infects anywhere from 3-15 % of cystic fibrosis (CF) patients and in recent epidemiologic assessments, S. maltophilia prevalence in CF is increasing. Presence of S. maltophilia has been linked to poor outcomes including decreased time to exacerbation, increased risk of death or transplant, CF related diabetes, and decreased lung function. While S. maltophilia has not been proven causative for these outcomes, it can promote lung inflammation, is inherently multidrug resistant, and is increasing in prevalence. Despite its prevalence and clinical correlations, understanding of S. maltophilia virulence and response to host defense lags far behind other CF pathogens. Here we report the draft genomes of two CF clinical isolates of S. maltophilia. S. maltophilia AU30115 was collected from an adult CF patient in Texas, USA in 2014 and S. maltophilia AU32848 was collected from an adult CF patient in Nebraska, USA in 2015. These isolates are susceptible to gentamicin at 100 ug/mL, and genetically traceable via conjugation and electroporation and will serve as model CF S. maltophilia isolates for genetic studies